DFTX

Definium Therapeutics, Inc.

NasdaqGSUSDEQUITY DELAYED

44.97

▼ 0.43 (0.95%)

MARKET · —

Price

Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw

Open

44.87

Prev close

45.40

Day high

46.50

Day low

44.81

Volume

1.35M

Market cap

—

P/E (TTM)

—

52W range

8.70 – 49.70

Trailing performance

Price return · vs SPY

Returnvs SPY

+5.35% +6.7%

+4.61% +0.9%

+98.28% +95.2%

+162.17% +151.1%

YTD

+235.40% +223.1%

+375.24% +355.2%

+987.41% +913.2%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Free account

3 more panels on DFTX open with an account.

Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.

Create free account Sign in

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Financial statements

As reported · 5 years

Blank means not reported, not zero

No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.

Line item	2025	2024	2023	2022	2021	YoY
Net income	-$183.79M	-$108.68M	-$95.73M	-$56.80M	—	-69.1%
Depreciation & amortisation	$0	$527.00K	$3.16M	$3.18M	—	-100.0%
Stock-based compensation	$20.10M	$16.91M	$15.18M	$13.71M	—	+18.8%
Change in working capital	$9.44M	-$3.34M	$6.28M	-$3.78M	—	+382.2%
Operating cash flow	-$131.56M	-$79.13M	-$64.36M	-$50.14M	—	-66.3%
Investing cash flow	-$151.61M	$0	—	$0	-$297.00K	—
Financing cash flow	$267.27M	$253.20M	$21.85M	$59.05M	—	+5.6%
Free cash flow	-$131.56M	-$79.13M	-$64.36M	-$50.14M	—	-66.3%
End cash position	$257.84M	$273.74M	$99.70M	$142.14M	—	-5.8%

Line item

2025

2024

2023

2022

2021

YoY

Net income

-$183.79M

-$108.68M

-$95.73M

-$56.80M

—

-69.1%

Depreciation & amortisation

$527.00K

$3.16M

$3.18M

—

-100.0%

Stock-based compensation

$20.10M

$16.91M

$15.18M

$13.71M

—

+18.8%

Change in working capital

$9.44M

-$3.34M

$6.28M

-$3.78M

—

+382.2%

Operating cash flow

-$131.56M

-$79.13M

-$64.36M

-$50.14M

—

-66.3%

Investing cash flow

-$151.61M

—

-$297.00K

—

Financing cash flow

$267.27M

$253.20M

$21.85M

$59.05M

—

+5.6%

Free cash flow

-$131.56M

-$79.13M

-$64.36M

-$50.14M

—

-66.3%

End cash position

$257.84M

$273.74M

$99.70M

$142.14M

—

-5.8%

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

44.30

+1.52% from price

SMA 20

43.93

+2.24% from price

SMA 50

41.62

+7.90% from price

SMA 100

31.88

+41.06% from price

SMA 200

23.47

+91.38% from price

EMA 12

44.59

+0.84% from price

EMA 26

43.57

+3.22% from price

EMA 50

40.39

+11.34% from price

RSI (14)

54.4

Neutral

MACD (12,26,9)

1.03

Hist -0.09

ATR (14)

2.94

6.54% of price

Realised vol 30D

59.5%

Annualised

Bollinger upper

47.19

20, 2σ

Bollinger lower

40.66

20, 2σ

50 / 200 cross

Golden

41.62 vs 23.47

Trend bias

Above 200

+91.38%

Options chain

Account required

ExpirySpot 44.97

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.11

More volatile than market

Correlation to SPY

0.18

Largely independent

Realised vol 30D

59.5%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-24.8%

Peak to trough

Max drawdown 5Y

-95.2%

Peak to trough

ATR 14

2.94

6.54% of price

Beta (reported)

—

5Y monthly, from filing

Headlines

DFTX · links out to the publisher

Definium Therapeutics Announces New Employee Inducement Grants Business Wire · 5d ago Weekly Roundup on the Cannabis Sector & Psychedelic Sector Market Exclusive · 5d ago Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus Simply Wall St. · 9d ago Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)? Simply Wall St. · 9d ago Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT Simply Wall St. · 9d ago Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says MT Newswires · 9d ago RBC Adjusts PT on Definium Therapeutics to $66 From $57, Keeps Outperform Speculative Risk Rating MT Newswires · 10d ago Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study MarketBeat · 10d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.